Lipoprotein abnormalities: A potential consequence of chronic kidney disease

Author:

Ahi Rajinderjit Singh1,Singh Sandeep1ORCID,Kumar Umesh2ORCID,Paul Basharat Azhar3

Affiliation:

1. Adesh Institute of Medical Sciences and Research, Bathinda, Punjab, India

2. Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences, Rohtak, Haryana, India

3. MM Institute of Medical Science and Research, Mullana, Haryana, India

Abstract

: Chronic kidney disease (CKD) is marked by kidney damage or a glomerular filtration rate (GFR) of less than 60 mL/min/1.73 m for at least three months, regardless of the underlying etiology. When a variety of renal problems are present, albuminuria defined as an albumin-to-creatinine ratio >30 mg/g in two out of three spot urine samples can serve to determine kidney failure.The estimated global rate of CKD is 13.4%. Nearly every aspect of biological life involves lipids. A few of these include acting as hormones or as precursors to hormones, providing energy, storing function and metabolic fuels, acting as functional and structural molecules in bio-membranes and forming insulation to aid in nerve transmission or prevent heat loss. The blood contains a variety of lipoproteins. They are chylomicrons, very-low density lipoprotein (VLDL), intermediate-density lipoprotein (IDL), low-density lipoprotein (LDL) and high-density lipoprotein (HDL), in descending sequence of increasing density. Less dense lipoproteins result from lower protein/lipid ratios. Although some lipoproteins carry cholesterol in its natural "free" alcohol form (the cholesterol-OH group facing the water surrounding the particles), all lipoproteins contain identical amounts of cholesterol. Other lipoproteins carry cholesterol in the form of fatty acyl esters, sometimes referred to as cholesterol esters. Triacylglycerol and cholesterol, which were not employed in the production of bile acids, are converted by the liver into VLDL molecules. The aim of the study was to assess the Lipid levels in CKD and study the correlation between eGFR (which is a marker of severity of CKD) and lipid levels in CKD. Thepresent study was an observational study. The study was conducted over a period of six months on 180 patients. Blood samples were obtained in Becton Dickinson's commercially available red-capped tubes vacutainers (BD). After that, blood samples were left undisturbed at room temperature for 15-30 minutes to coagulate. For 5 minutes, the tubes were centrifuged at 3000 rpm. After centrifugation, the sample solution (serum) was transferred to a fresh polypropylene tube with a Pasteur pipette. Lipid profile and serum creatinine were done on fully automated SYSMEX BX-3010. Our results show that mean and standard deviation of serum cholesterol, serum triglycerides, HDL, VLDL and LDL with -value between males and females in the different stages of CKD shows a statistically significant difference between stage II, III B, IV and stage V. The present study highlights the progressive increase in serum cholesterol, serum triglycerides, VLDL, LDL levels as CKD advances through its stages. A progressive decline in HDL levels as CKD also advances through its stages. The correlations between eGFR and various biomarkers in the stages of CKD shed light on the complex interactions between renal function, lipid metabolism.

Publisher

IP Innovative Publication Pvt Ltd

Reference41 articles.

1. Kovesdy CP, Epidemiology of chronic kidney disease: An update 2022.Kidney Int Suppl (2011) 2022;12(1):7-11

2. Wanner C, Tonelli M, KDIGO clinical practice guideline for lipid management in CKD: Summary of recommendation statements and clinical approach to the patient.Kidney Int 2014;85(6):1303-9

3. Hill NR, Fatoba ST, Oke JL, Hirst JA, O’callaghan CA, Lasserson DS, Global prevalence of chronic kidney disease: A systematic review and meta-analysis.PLoS One 2016;11(7):e0158765

4. Collaborators GBD 2015 Disease and Injury Incidence and Prevalence, S, Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: A systematic analysis for the Global Burden of Disease Study 2015.Lancet 2016;388(10053):1545-1602

5. Rizvi SM, Muhit MM, Tao S, Kalam A, Rahman ML, Alom MK, Treatment and prevention of chronic kidney disease.N Am Acad Res 2023;6(1):186-219

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3